In December 2024 NICE approved Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation.
This is for patients that have progressed after at least 1 line of endocrine therapy plus a cyclin-dependent kinase (CDK) 4 and 6 inhibitor after at least 12 months of treatment with both.
Treatment criteria can be found on the national CDF list at:
- https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/
- or on the application form(s) on the Blueteq site.
The ESR1 test is done on a blood test to look for the mutation within circulating tumour DNA; at present this test is supplied through the Northwest Genomics Laboratory Hub (NW GLH).
The test is not available on tumour, as tumour biopsies are not the most appropriate way to pick up this mutation.
You can find out more on the North West Genomic Medicine Service website here.
Result Interpretation
If advice is needed about interpretation, you can refer the case to the North East Yorkshire Genomic Tumour Advisory Board. Email them at [email protected]